
Keywords: پایان محصول گلیکسی; AGE; Advanced glycation endproduct; CML; Nε-(carboxymethyl)lysine; CEL; Nε-(carboxyethyl)lysine; MG-H1; 5-hydro-5-methylimidazolone; MMP; Matrix metalloproteinase; TIMP; Tissue inhibitor of metalloproteinase; Type 1 diabetes; AGEs; MMPs; TIMP-1; Cardiov